FIBRINOGEN RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

摘要

Compounds of the following general formula (I) and pharmaceutically acceptable salts thereof. According to the present invention, compounds which antagonize the action of fibrinogen receptors and, therefore, have a high platelet aggregation-inhibiting activity, an in vivo stability against the cleavage with proteotytic enzymes and an excellent bioavailability are provided, which are useful as agents for inhibiting platelet aggregation. The pharmaceutical preparations comprising the compounds as active ingredient are very effective for preventing platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy, and preventing platelet thrombosis, thromboembolism and reocclusion after angioplasty of coronary and other arteries and after coronary artery bypass procedures. These preparations are also be very effective for preventing unstable angina and myocardial infraction, improving peripheral circulatory bloodstream and inhibiting blood coagulation during extracorporeal circulation.